[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer]. [electronic resource]
Producer: 20130502Description: 380-5 p. digitalISSN:- 1563-258X
- Aged, 80 and over
- Androgen Antagonists -- adverse effects
- Antibodies, Monoclonal, Humanized -- adverse effects
- Antineoplastic Agents, Hormonal -- adverse effects
- Bone Density -- drug effects
- Bone Density Conservation Agents -- adverse effects
- Denosumab
- Diphosphonates -- adverse effects
- Gonadotropin-Releasing Hormone -- agonists
- Humans
- Male
- Neoplasm Staging
- Osteoclasts -- drug effects
- Osteoporosis -- chemically induced
- Osteoporotic Fractures -- chemically induced
- Prostatic Neoplasms -- drug therapy
- RANK Ligand -- antagonists & inhibitors
- Randomized Controlled Trials as Topic
- Selective Estrogen Receptor Modulators -- adverse effects
- Spinal Fractures -- chemically induced
- Toremifene -- adverse effects
No physical items for this record
Publication Type: Case Reports; Comparative Study; English Abstract; Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.